Search Results
Mar 19, 2026, 05:03 ET RIMAN impulsa a la acción en la Convención de América del Norte de 2026
norteamericano.Uno de los aspectos más destacados de la convención fue la introducción de los productos para el cuidado de la piel recientemente actualizados ICD Radiansome™100. El acceso exclusivo de RIMAN a una forma patentada de síntesis de liposomas, conocida como Microfluidizer Processor, permitió la dedicación
More news about: RIMAN Inc.
Mar 18, 2026, 16:05 ET Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary
More news about: Talphera, Inc.
Mar 16, 2026, 03:02 ET Cynosure Lutronic Perkuat Posisi di Asia Pasifik -- Kawasan Perangkat Estetika Medis dengan Pertumbuhan Tercepat di Dunia, Melalui Perolehan Dua Izin Regulasi Clarity II™ di Tiongkok dan Jepang pada Februari 2026
CEO, Cynosure Lutronic.Tiongkok: Persetujuan Regulasi Di Tiongkok, Clarity II™ (dipasarkan dengan nama CLARITY II™ ICD) memperoleh izin untuk digunakan di institusi medis pada 12 Februari 2026.Nama Produk: Clarity II™Indikasi
More news about: Cynosure Lutronic
Mar 13, 2026, 05:42 ET RIMAN donne l'impulsion à la convention 2026 Amérique du Nord
l'accélération de la dynamique du marché nord-américain.L'un des points forts de la convention a été l'introduction des produits de soins de la peau ICD Radiansome™100, récemment améliorés. L'accès exclusif de RIMAN à une forme brevetée de production des liposomes, connue sous le nom de Microfluidizer
More news about: RIMAN Inc.
Mar 12, 2026, 03:20 ET RIMAN bringt Schwung in die 2026 North America Convention
deutlich die zunehmende Dynamik des nordamerikanischen Marktes.Ein wichtiger Höhepunkt des Kongresses war die Einführung der neu überarbeiteten ICD Radiansome™100 Hautpflegeprodukte. RIMANs exklusiver Zugang zu einer patentierten Form der Liposomensynthese, bekannt als Microfluidizer Processor, ermöglichte
More news about: RIMAN Inc.
Mar 10, 2026, 21:52 ET RIMAN Ignites Momentum at 2026 North America Convention
demonstrated the accelerating momentum of the North American market.A key highlight of the convention was the introduction of the newly upgraded ICD Radiansome™100 skincare products. RIMAN's exclusive access to a patented form of liposome synthesis, known as the Microfluidizer Processor, allowed for
More news about: RIMAN Inc.
Mar 10, 2026, 21:22 ET RIMAN Ignites Momentum at 2026 North America Convention
demonstrated the accelerating momentum of the North American market.A key highlight of the convention was the introduction of the newly upgraded ICD Radiansome™100 skincare products. RIMAN's exclusive access to a patented form of liposome synthesis, known as the Microfluidizer Processor, allowed for
More news about: RIMAN Inc.
Mar 09, 2026, 01:35 ET Cynosure Lutronic củng cố vị thế tại khu vực APAC -- khu vực tăng trưởng nhanh nhất thế giới về thiết bị thẩm mỹ y khoa, với việc Clarity II™ được phê duyệt pháp lý tại Trung Quốc và Nhật Bản, tháng 2 năm 2026
lý Tại Trung Quốc, Clarity II (được tiếp thị với tên CLARITY II ICD) đã nhận được phê duyệt pháp lý để sử dụng tại các cơ sở y tế kể từ ngày 12 tháng 2 năm 2026. Tên sản phẩm: Clarity II ICDCác chỉ định được phê duyệt:Laser 755nm
More news about: Cynosure Lutronic
Mar 05, 2026, 03:24 ET RIMAN galardonado con el PREMIO iF DESIGN 2026, fortaleciendo su liderazgo de marca global
RIMAN, una marca coreana premium de cuidado de la piel y bienestar, ha anunciado que su línea ICD Dermatology Line, con boosters, sueros y cremas, ha recibido el PREMIO iF DESIGN 2026 en la categoría de DISEÑO de envases. El empaque reimagina el ingrediente
More news about: RIMAN Inc.
Mar 03, 2026, 11:16 ET New Research from The Fuchsia Tent Shows Making Midlife Women Visible in Employer Health Data Could Save U.S. Companies $26.6B
that population being in some stage of the menopausal transition. Symptoms like anxiety, insomnia, joint pain, and cognitive changes are captured in ICD-10 coding as standalone conditions and never linked to menopause, leading to widespread mis- and underdiagnosis that costs U.S. employers an estimated
More news about: The Fuchsia Tent
Mar 03, 2026, 05:33 ET RIMAN、iF DESIGN AWARD 2026を受賞 ― グローバルブランドとしてのリーダーシップを強化
韓国のプレミアム・スキンケアおよびウェルネス・ブランドであるRIMANは、ブースター、美容液、クリームを特徴とするICD Derma 製品ライン（ICDダーマライン、グローバルでは「ICD Dermatology 製品ライン」として展開）が、iF DESIGN AWARD 2026のパッケージデザイン部門を受賞しました。このパッケージは、RIMANの代表的成分であるGiant BYoungPool™（Giant Centella Asiatica）を、ミニマルかつ洗練されたデザインで再構築したものです。Lava
More news about: RIMAN Inc.
Mar 02, 2026, 23:09 ET Cynosure Lutronic、Clarity II™の中国・日本における薬事承認取得により、世界で最も急成長している美容医療機器市場であるAPACでの競争力をさらに強化（2026年2月）
Lutronicの競争力が着実に高まっていることを示すものです」と述べています。中国：薬事承認中国において、Clarity II（CLARITY II ICDとして販売）は、2026年2月12日付で医療機関での使用に関する薬事承認を取得しました。製品名：Clarity II ICD承認された適応：755nmレーザー：頬のしわを軽減する用途で承認を取得1064nmレーザー：ムダ毛を減らす用途で承認を取得今回の承認により、中国の規制下にある臨床現場において、複数の治療用途に対して単一の統合プラットフォームを使用することが正式に認められました。日本：薬事承認日本において、Clarity
More news about: Cynosure Lutronic
Mar 02, 2026, 08:30 ET Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary
More news about: Talphera, Inc.
Feb 27, 2026, 10:13 ET RIMAN recibe el iF DESIGN AWARD 2026 y consolida su liderazgo global
RIMAN, marca coreana prémium de cuidado de la piel y bienestar, anunció que su línea ICD Dermatology, que incluye potenciadores, sérums y cremas, recibió el premio iF DESIGN AWARD 2026 en la categoría de Diseño de Empaque. El empaque reinventa
More news about: RIMAN Inc.
Feb 27, 2026, 05:49 ET Cynosure Lutronic旗下Clarity II™獲中日雙重監管批准 -- 強化其在亞太醫美設備市場的競爭力
Lutronic在亞太地區的市場競爭力正持續提升。」中國：監管許可在中國，Clarity II（商品名稱為CLARITY II ICD）已獲得監管批准，自2026年2月12日起可在醫療機構使用。 產品名稱：Clarity II ICD 批准適應症： 755nm激光 - 獲准用於改善面頰部皺紋1064nm激光 - 獲准用於去除體部多餘毛髮該許可明確，該單一集成平台可在國內合規臨床環境中，用於多種治療場景。日本：監管許可在日本，Clarity
More news about: Cynosure Lutronic
Feb 27, 2026, 04:21 ET RIMAN wird mit dem iF DESIGN AWARD 2026 ausgezeichnet und stärkt damit seine globale Markenführerschaft
RIMAN, eine koreanische Premium-Hautpflege- und Wellness-Marke, gab bekannt, dass ihre ICD Dermatology Line mit Boostern, Seren und Cremes den iF DESIGN AWARD 2026 in der Kategorie Verpackungsdesign erhalten hat. Die Verpackung stellt den charakteristischen
More news about: RIMAN Inc.
Feb 27, 2026, 04:09 ET RIMAN reçoit l'iF DESIGN AWARD 2026, renforçant ainsi sa position de leader mondial de la marque
RIMAN, une marque coréenne haut de gamme de soins de la peau et de bien-être, a annoncé que sa ligne ICD Dermatology, comprenant des boosters, des sérums et des crèmes, a reçu l'iF DESIGN AWARD 2026 dans la catégorie Packaging Design. L'emballage réimagine
More news about: RIMAN Inc.
Feb 26, 2026, 23:05 ET RIMAN Honored with iF DESIGN AWARD 2026, Strengthening Its Global Brand Leadership
/PRNewswire/ -- RIMAN, a premium Korean skincare and wellness brand, announced its ICD Dermatology Line, featuring boosters, serums, and creams, has received the iF DESIGN AWARD 2026 in the Packaging Design category. The packaging reimagines
More news about: RIMAN Inc.
Feb 26, 2026, 22:45 ET RIMAN Honored with iF DESIGN AWARD 2026, Strengthening Its Global Brand Leadership
/PRNewswire/ -- RIMAN, a premium Korean skincare and wellness brand, announced its ICD Dermatology Line, featuring boosters, serums, and creams, has received the iF DESIGN AWARD 2026 in the Packaging Design category. The packaging reimagines
More news about: RIMAN Inc.
Feb 26, 2026, 21:36 ET Cynosure Lutronic bolsters its strength in APAC -- The world's fastest-growing medical aesthetics device region, with dual regulatory approvals for the Clarity II™ in China and Japan, February 2026
Approval In China, Clarity II (marketed as CLARITY II ICD) has received regulatory approval for use in medical institutions as of 12th February 2026. Product Name: Clarity II ICD Approved Indications: 755nm
More news about: Cynosure Lutronic
Feb 25, 2026, 10:38 ET IMO Health Operationalizes Mondo Rare Disease Knowledge, Bringing Greater Precision to Diagnosis and Research
terminology for rare disease patient identification in electronic health records identified 5.5 times more diseases and 20% more patients compared to standard ICD-10 coding systems. With the Mondo integration, coverage for rare genetic disease diagnoses will expand from 51% to 75% in Mondo while maintaining over
More news about: Intelligent Medical Objects, Inc.
Feb 16, 2026, 08:00 ET Immune Checkpoint Inhibitor Therapy May Reduce Asthma Exacerbations
with asthma who were undergoing immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma. Asthma subtypes were classified using ICD-10 codes (J45.2 - J45.909). Asthma exacerbation rates, defined as acute asthma exacerbation or status asthmaticus, were compared at 6, 12 and 24 months
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 12, 2026, 06:33 ET BIOTRONIK launcht weltweit erstes CRT-D-System mit Zulassung für Stimulation des Reizleitungssystems
Die ICD- und CRT-D-Familie Acticor Sky und Rivacor Sky kombiniert physiologische Stimulation mit modernstem HerzrhythmusmanagementBERLIN, 12. Februar 2026 /PRNewswire/ -- BIOTRONIK gab heute die Markteinführung
More news about: Biotronik
Feb 12, 2026, 05:27 ET BIOTRONIK Expands Cardiac Rhythm Care by Launching World's First CRT-D Systems Approved for Conduction System Pacing
Acticor Sky and Rivacor Sky ICD and CRT-D Family Integrate Physiological Pacing Strategies with Advanced Arrhythmia Management BERLIN, Feb. 12, 2026 /PRNewswire/ -- BIOTRONIK today announced the launch of the
More news about: Biotronik
Feb 02, 2026, 10:08 ET El Texas Cardiac Arrhythmia Institute en el Centro Médico de St. David es el primero en los EE. UU. en implantar un nuevo cable de desfibrilación aprobado por la FDA
implantar un nuevo cable de desfibrilación aprobado por la FDA, un cable especializado y aislado que se conecta a un desfibrilador cardioversor implantable (ICD) o a un dispositivo de terapia de resincronización cardíaca (CRT-Ds) en el corazón y corrige el ritmo anormal. El cable de desfibrilación es el cable
More news about: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center